2026-08-08

ResMed (RMD) Stock Falls 5% Despite Record $1.46B Quarter and EPS Beat - First-Ever FY2027 Guidance Spooks Investors

Written & reviewed by the TradeSmrt editorial team · 2026-08-08

In this article

What Happened
Why a Beat Still Triggered a Sell-Off - ResMed's First-Ever FY2027 Outlook
What a Recall-and-M&A "Transition Quarter" Signals
The Bigger Backdrop - Why GLP-1 Weight-Loss Drugs Keep Coming Up in ResMed Coverage
What to Take Away From This
Sources

What Happened

After the market closed on August 6, ResMed (NYSE: RMD), the Australian-founded medical device maker best known for its CPAP sleep apnea machines, reported fourth-quarter results for fiscal year 2026 (ended June 30). Revenue came in at $1.46 billion, up 9% year-over-year (8% on a constant-currency basis) and a new quarterly record for the company. Non-GAAP diluted earnings per share reached $2.95, beating the $2.88 consensus estimate and up 16% from a year earlier. For the full fiscal year, non-GAAP diluted EPS totaled $11.17, up 17%, while operating cash flow hit $1.8 billion and free cash flow reached $1.6 billion. On paper, this was a clean beat-and-record quarter across nearly every headline metric.

The market's reaction told a different story. On August 7, the first trading session after the release, ResMed shares fell as much as 5.5% in premarket trading and closed the regular session down 5.22% from the prior close of $223.24. That put the stock back toward the lower end of its 52-week range of $180.26 to $293.81. In a quarter where both revenue and earnings cleared Wall Street's bar, the reason shares still dropped more than 5% wasn't the numbers that had just been reported - it was the numbers the company projected for the year ahead.

Why a Beat Still Triggered a Sell-Off - ResMed's First-Ever FY2027 Outlook

This earnings release marked the first time ResMed issued formal guidance covering the entirety of fiscal year 2027 (July 2026 through June 2027). The company's core revenue growth outlook: 5-7%, noticeably below the 8% constant-currency growth just posted for FY2026. Investors weighed that forward-looking number far more heavily than the quarter that had already closed. A strong quarter in the rearview mirror mattered less than a company-issued signal that growth is set to decelerate over the next twelve months.

Two concrete factors were baked into that cautious guidance. The first involves a field safety action tied to ResMed's Astral ventilator, a life-support device. The action triggered a temporary suspension of Astral sales, and life-support device revenue plunged 45% in the Americas and 38% in the rest of the world during the fourth quarter alone. Management said the fallout would create a $75 million headwind to FY2027 revenue. GAAP gross margin came in at 58.8% for the quarter, weighed down by $41.9 million in costs tied to the field safety notification. The second factor is dilution from portfolio restructuring. ResMed has agreed to sell its MatrixCare software subsidiary, a deal expected to close in the first quarter of FY2027 and estimated to reduce EPS by roughly $0.30. On top of that, the company completed its $340 million acquisition of Noctrix Health, a wearable-device maker focused on restless leg syndrome, which management estimates will dilute EPS by a further $0.20.

Wall Street's response to all of this was split. Wells Fargo cut its price target from $225 to $215 while maintaining an Equal-Weight rating, citing FY2027 revenue guidance that came in below consensus. RBC Capital moved in the opposite direction, raising its target from $234 to $244. That divergence between two major banks looking at the same quarter and the same guidance suggests this wasn't a clear-cut negative story, but rather a case of differing views on how to weigh near-term growth deceleration against a longer restructuring arc.

What a Recall-and-M&A "Transition Quarter" Signals

ResMed's reaction illustrates a pattern that shows up repeatedly in medical device earnings: the "transition quarter," where a genuinely solid quarter collides with multiple structural changes happening at once. Here, ResMed is simultaneously working through (1) a safety-driven product recall, (2) the divestiture of a non-core business, and (3) a new-market acquisition. In situations like this, management's forward-looking, quantified estimate of how those changes will weigh on revenue and margins over the next several quarters tends to matter more to the stock than last quarter's results. Notably, the company reported that gross margin actually expanded 90 basis points year-over-year in the quarter and 290 basis points for the full fiscal year - genuine profitability improvement. But with one-time Astral-related costs and M&A dilution layered on top, the market's attention gravitated toward the lowered growth outlook rather than the improved margin trend.

The contrast is instructive when placed next to two other earnings reactions covered on this site this week: Twilio (Twilio Stock Soars 30%) and Sezzle (Sezzle Stock Plunges 24%). Twilio beat estimates and raised guidance toward acceleration, and its stock jumped. Sezzle beat estimates but its guidance implied deceleration, and its stock plunged. ResMed sits somewhere in between - last quarter's results were unambiguously strong, but the company's first-ever full-year outlook for the coming fiscal year, at 5-7%, landed below the roughly 8% growth pace the market had grown used to, and that gap between "what just happened" and "what's coming" is what moved the stock. At the same time, ResMed said it plans to return more than $1.85 billion to shareholders through buybacks and dividends in FY2027, alongside a 10% increase to its quarterly dividend, to $0.66 per share. The company lowered near-term growth expectations while simultaneously signaling confidence in its cash-generation ability - which is part of why this decline reads less like a fundamental impairment and more like a recalibration tied to a recall-and-restructuring transition.

The Bigger Backdrop - Why GLP-1 Weight-Loss Drugs Keep Coming Up in ResMed Coverage

Understanding this move fully requires revisiting a structural debate that has trailed ResMed for the past couple of years. As GLP-1 weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Mounjaro have gone mainstream, one persistent bear case has been that meaningful weight loss across a large population could shrink the pool of sleep apnea patients over time, and with it, long-run demand for CPAP devices. This site has covered that ripple effect before, when Novo Nordisk and Eli Lilly reported their own results (Novo Nordisk Falls Despite Raised Guidance, Eli Lilly Beats but Falls), and ResMed has consistently been named as one of the device makers most directly exposed to that narrative. The fact that fourth-quarter revenue still grew 9% is, at minimum, evidence that the demand-destruction thesis hasn't materialized yet in the reported numbers. But it's difficult to rule out that lingering uncertainty over long-run demand played some role in how conservatively management chose to frame FY2027 growth. Intensifying competition on new device launches and pricing pressure in the masks-and-accessories category add another layer to why the market isn't fully crediting the margin improvement that did show up in the quarter.

Seen this way, the guidance cut looks less like a simple sum of two one-time events and more like a blended reflection of several layers of uncertainty at once. Management quantified the parts that could be quantified - the $75 million Astral revenue headwind and roughly $0.50 of combined EPS dilution from the two deals - but the harder-to-model long-run risk from shifting GLP-1-driven demand likely got folded into the conservative shape of the 5-7% growth range rather than broken out as its own line item. That distinction matters for how investors should read the quarter: taking management's disclosed, quantified factors at face value and assuming they fully explain the drop would be incomplete without also weighing how much of that undisclosed, qualitative risk is baked into the guidance range itself. It's also worth noting that ResMed shares were already down more than 20% from their highs earlier this year, well before the Astral recall became public - a sign that the GLP-1 demand debate had been weighing on the stock independently of this quarter's specific headwinds.

What to Take Away From This

A first-ever forward guidance figure can outweigh a beaten quarter. Even when revenue and EPS clear consensus, a newly issued outlook that implies slower growth than the recent trend tends to dominate the stock's reaction more than the quarter that just closed.
Margin improvement and revenue deceleration can coexist. ResMed's gross margin actually expanded for the year, yet the stock still fell - a reminder to check which metric the market is actually pricing, not just which one improved.
Quantify one-time events like recalls and M&A directly. When a company discloses specific figures - here, a $75 million revenue headwind from the recall and $0.30 plus $0.20 of EPS dilution from two deals - those numbers can be modeled into forward estimates rather than treated as vague risk factors.
A split among analysts is a signal to avoid snap conclusions. Wells Fargo cut its target while RBC raised its own on the same release - when major banks disagree this sharply, it's worth weighing both sides' reasoning rather than following either one alone.

Sources

This article synthesizes and analyzes the reporting below in our own words - it is not a reproduction of the original text. For the latest figures and full detail, please refer to the original sources.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data yourself before making any investment decision.